Clinical Research Papers:
Incidence and physiological mechanism of carboplatin-induced electrolyte abnormality among patients with non-small cell lung cancer
Metrics: PDF 1386 views | HTML 1255 views | ?
Yushui Ma1,2,*, Likun Hou3,*, Fei Yu1,*, Gaixia Lu1, Shanshan Qin1, Ruting Xie4, Huiqiong Yang4, Tingmiao Wu1, Pei Luo1, Li Chai1, Zhongwei Lv1, Xiaodong Peng5, Chunyan Wu3 and Da Fu6
1 Department of Nuclear Medicine, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
2 Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, College of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China
3 Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
4 Department of Pathology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
5 Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China
6 Central Laboratory for Medical Research, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
* These authors have contributed equally to this work
Xiaodong Peng, email:
Chunyan Wu, email:
Da Fu, email:
Keywords: carboplatin; hyponatremia; hypokalemia; dehydration; FDA adverse event reporting system
Received: May 01, 2016 Accepted: October 14, 2016 Published: October 21, 2016
To clarify the association between carboplatin and electrolyte abnormality, a pooled-analysis was performed with the adverse event reports of non-small cell lung cancer patients. A total of 19901 adverse events were retrieved from the FDA Adverse Event Reporting System (FAERS). Pooled reporting odds ratios (RORs) and 95% CIs suggested that carboplatin was significantly associated with hyponatremia (pooled ROR = 1.57, 95% CI 1.18–2.09, P = 1.99×10-3) and hypokalemia (pooled ROR = 2.37, 95% CI 1.80–3.10, P = 5.24×10-10) as compared to other therapies. In addition, we found that dehydration was frequently concurrent with carboplatin therapy (pooled ROR = 2.01, 95% CI 1.52–2.66, P = 8.37×10-7), which may prompt excessive water ingestion and decrease serum electrolyte concentrations. This information has not been mentioned in the FDA-approved drug label and could help explain the physiological mechanism of carboplatin-induced electrolyte abnormality. In conclusion, the above results will facilitate clinical management and prompt intervention of life-threatening electrolyte imbalance in the course of cancer treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.